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Abstract Cancer is a complex disease and unfortunately understanding how the components of the cancer system
work does not help understand the behavior of the system as a whole. In the words of the Greek
philosopher Aristotle “the whole is greater than the sum of parts.” To date, thanks to improved information
technology infrastructures, it is possible to store data from each single cancer patient, including clinical
data, medical images, laboratory tests, and pathological and genomic information. Indeed, medical archive
storage constitutes approximately one-third of total global storage demand and a large part of the data are
in the form of medical images. The opportunity is now to draw insight on the whole to the benefit of each
individual patient. In the oncologic patient, big data analysis is at the beginning but several useful
applications can be envisaged including development of imaging biomarkers to predict disease outcome,
assessing the risk of X-ray dose exposure or of renal damage following the administration of contrast
agents, and tracking and optimizing patient workflow. The aim of this review is to present current evidence
of how big data derived from medical images may impact on the diagnostic pathway of the oncologic
patient.
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Introduction
Big Data initiatives are aimed at drawing inferences 
from large datasets that are not derived from carefully 
controlled information [1]. In medicine, the basic idea 
behind using big data is to learn new knowledge from 
every patient we have ever treated and apply this knowl-
edge to the next patient [2]. This concept will give future 
generations the opportunity to bring into existence a “fast 
learning health system” to the benefit of each individual 
patient. In the era of precision medicine, this evolution-
ary concept may lead to a comprehensive and individual 
approach to treatment [3]. In oncology, where information 
collected from the single patient is extremely variegated, 
big data analysis could allow definition of specific and 
efficient diagnostic and therapeutic pathways, improv-
ing patient workflow and quality of life. The aim of this 
review is to collect current evidence and to envisage how 
in the future big data may impact on the diagnostic path-
way of the oncologic patient.
Big data in oncologic imaging: the rationale
The following key concepts related to big data should be 
considered when approaching oncologic imaging issues:
1. Opposite to traditional hypothesis-driven cancer 
research [4], big data research may be launched regard-
less of whether important questions are identified.
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2. Big data in health consists in datasets that are too big, 
too inhomogeneous, and too complex for healthcare 
providers to process and interpret with existing tools 
[5].
3. Big data is not about implementing one piece of tech-
nology, it also includes data mining and machine learn-
ing and offers potential alternative approaches to lever-
aging large data resources [6, 7].
Cancer fits well into these concepts, as it is a complex 
disease that changes, evolves, and adapts to the surround-
ing environment. Its evolution could be better understood 
by collecting information from different sources—e.g., 
demographic, genetic, imaging, treatment, and outcomes—
that could then be processed as big data. In the last two 
decades, the development of efficient information technol-
ogy (IT) infrastructures has allowed digitalization and elec-
tronic integration of healthcare information [8]. In 2012, 
AT&T estimated that the storage requirements for medi-
cal archives were increasing by 20–40 % each year, with 
medical images constituting one-third of total global stor-
age demand [9, 10]. Today, an average size hospital man-
ages approximately 665 TB of patient data, corresponding 
to approximately 140.000 DVDs [11].
Big data has the potential to dramatically reshape can-
cer care landscape, improving quality and efficiency in 
every cancer setting [12] (Fig. 1). In the field of oncologic 
imaging, big data may allow the development of tools for 
baseline assessment and for quantification of anatomic and 
functional changes over time. Quantitative imaging bio-
markers will contribute to tailoring treatment to each indi-
vidual patient. Extraction of data from radiation and con-
trast agent dose registries will allow to explore dose effects 
on subjects with cumulative X-rays, computed tomogra-
phy (CT) scans, radiation therapy treatments, or nuclear 
medicine examinations and minimize contrast-induced 
nephrotoxicity by stratifying cancer patients into risk cat-
egories. Finally, processing of big data could support the 
development of optimized clinical workflows and in the 
end increase the management efficiency of comprehensive 
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cancer centers and of tertiary health facilities in general 
[13].
Big data in oncologic imaging: current 
developments
Today, most of what we know about cancer comes from 
a tiny subset of patients, i.e., the 3 % who are enrolled in 
clinical trials; hence, those data are non-representative of 
the entire cancer population [14]. The remaining 97 % gen-
erate potentially useful information that is lost, due to the 
fact that data collection is mostly non-structured. In recent 
years, publicly accessible medical repositories are being 
implemented with the aim of collecting data from different 
imaging modalities. The cancer imaging archive (TCIA), 
for example, provides a public repository of cancer images 
and related clinical data [15]. The repository was created 
with the support of the National Cancer Institute with the 
aim of collecting, curating, and managing a rich collection 
of oncologic imaging data to enable open-science research. 
[16]. At present, more than 26 million radiologic images 
contributed by 28 institutions and several thousand pathol-
ogy images are stored in this repository that is constantly 
increasing in size and variety [15]. In this chapter, we will 
review how the analysis of all this information benefits 
each individual patient.
Extracting the “dark matter” from medical images
In medical images, data are usually provided as an orderly 
set of gray scale pixel values; however, in this form data 
are not synonymous of information or knowledge. Indeed, 
of the estimated 80 % of hospital data that are represented 
by unstructured imaging data [11], very little are currently 
being used for diagnosis. Eliot Siegel from the University 
of Maryland compared the data hidden in a clinical image, 
i.e., data that cannot be directly observed with current tech-
nology, as the “dark matter in space” [17]. The main chal-
lenge for future generations will be to extract important and 
meaningful information from this dark matter. Improve-
ments in image analysis will reasonably bridge the gap 
between the visual content and its numeric representation, 
which includes encoded color and texture properties of an 
image, the spatial layout of objects, and geometric shape 
characteristics of anatomical structures. More and more 
diagnostic techniques are providing multi-modality imag-
ing, with challenging big data management issues. A mag-
netic resonance (MR) examination, for example, includes 
high-resolution morphological images and information on 
tissue perfusion and diffusion capturing complex in vivo 
flow patterns; similarly, CT dual-energy acquisitions 
include information on material decomposition and spectral 
imaging [18]. Furthermore, combining different imaging 
modalities at the hardware level (MR/PET, PET/CT) will 
open up a range of new opportunities for image analysis 
[5].
Pattern recognition software and tools for high-through-
put extraction of quantitative features have been imple-
mented in parallel to the increase in dataset size and infor-
mation. Conversion of images into mineable data and 
subsequent analysis for clinical decision support has paved 
the way to radiomics [1]. Radiomic data typically con-
tain first-, second-, and higher-order statistics that can be 
combined with other patient data to develop models with 
improved diagnostic, prognostic, and predictive accuracy.
Diagnostic X-ray dose exposure
During the past 30 years, radiologic procedures involving 
ionizing radiation have been increasingly used in clinical 
routine leading to a dramatic increase in individual patient 
dose exposure. Today, medical radiation comprises almost 
50 % of per capita radiation dose, compared with 15 % in 
the early 1980s [19]. Individual risk of developing radia-
tion-related cancer from any single imaging procedure is 
extremely low; however, repeated examinations may lead 
to a substantial increase in such risk [20]. Unfortunately, 
epidemiologic literature on low-dose effects of ionizing 
radiations is limited by statistical power. In the future, the 
opportunity to exploit large databases will help clarify the 
relationship between cancer-induced pathologies and low-
dose radiation levels [21, 22]. In particular, the introduc-
tion of radiation dose registries could be a valuable tool for 
patient monitoring and optimization of dose delivery. Col-
lected information should include (1) radiation dose distri-
butions and dose–volume metrics from treatment planning 
in radiotherapy (i.e., dose–volume histograms, the volume 
receiving a certain dose, minimum dose to a given volume, 
mean, maximum, and minimum dose); (2) X-ray doses 
from radiological imaging (i.e., volumetric CT dose index, 
dose-length product, dose-area product); and (3) gamma-
ray and other radioisotopes radiation doses from nuclear 
medicine imaging and treatment. A radiation dose registry 
may allow clinicians to compare dose levels to the averages 
of other national and international centers, in order to suc-
cessfully implement low-dose protocols. On the side, this 
will favor standardization, create higher patient confidence 
in radiation safety, and offer the opportunity for better qual-
ity assessment.
Regulations and guidelines, such as the European direc-
tive Euratom 97/43, 2013/59/EURATOM, and the Ameri-
can College of Radiology dose Whitepaper, express the 
need for facilities to track radiation dose for patient and 
population, and support the implementation for dose reg-
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EURATOM points out that health authorities will be more 
pervasive on inspecting the dosimetry applied to patients. 
Integrating the Healthcare Enterprise (IHE—www.ihe.net) 
is an initiative of professional societies aimed at collaborat-
ing with the industry in order to coordinate standards-based 
solutions to problems that span multiple vendors systems. 
The new IHE radiation exposure monitoring (REM) Profile 
facilitates the collection and distribution of the estimated 
patient radiation exposure information resulting from imag-
ing procedures and provides an implementation guide for 
vendors. By following this guide and participating in IHE 
Connectathon, vendors can release products that will inter-
operate to provide an exposure monitoring pipeline (http://
www.aapm.org/meetings/amos2/pdf/42-12234-94897-404.
pdf).
Some healthcare companies have already developed 
web-based dose management software to track and analyze 
patient radiation and iodine exposure across multi-facility, 
multi-modality, and multi-vendor imaging environments. 
These systems enable healthcare professionals to monitor 
radiation exposure and contrast media injection dose to 
their patients. In addition, these devices allow optimiza-
tion of acquisition protocols in order to find the right bal-
ance between image quality and dose, minimizing the risk 
of radiation-induced cancers (http://www.dicardiology.
com/article/software-help-manage-medical-imaging-radia-
tion-dose). On the technical side, there are several crucial 
aspects of dose tracking that deserve to be remembered. 
The first is dose capture: non-DICOM-SR compatible CT 
scanners store dose information as images rather than in 
numerical form, requiring an optical character recognition 
algorithm to capture the data. Second, information has to 
be associated with the patient to be exportable to dose reg-
istries such as the American College of Radiology (ACR) 
Dose Index Registry (DIR). This database, opened in 2011, 
represents the most substantial effort to standardize radia-
tion dose across the United States. Information related to 
dose indices to regional and national values is collected, 
anonymized, and stored across different care services. 
In 2013, the registry achieved dose index information on 
5.5 million CT examinations across 750 registered facili-
ties [23]. DIR is a data registry that allows facilities to 
compare their CT dose indices to regional and national 
values. Institutions are provided with periodic feedback 
reports comparing their results by body part and exam type 
to aggregate results (http://www.acr.org/Quality-Safety/
National-Radiology-Data-Registry/Dose-Index-Registry).
Big data and radiation oncology
Big data repositories include detailed 3-dimensional dosi-
metric and imaging data, and their changes over time. 
Of these, the National Radiation Oncology Registry was 
designed to collect information on cancer care delivery 
among patients treated with radiation therapy [24, 25]. 
Predictive models can be applied to the collected treat-
ment variables to assess patient outcome. In a pilot project, 
prostate cancer was selected as the initial disease site, and 
information was collected on clinical features, toxicity, and 
spatial and temporal dose distribution. Thanks to this pilot 
study, researchers may now identify best strategy options 
that allow patients to safely choose to do nothing or opt for 
mild treatments or surgery [26]. In the era of genomics, one 
may envision leveraging large repositories with detailed 
radiation therapy data, imaging data, and genomic pro-
files of tumor and normal tissue samples in order to better 
understand predictors of tumor control and risk of normal 
tissue injury, providing radiation oncologists the opportu-
nity to potentially offer personalized dose prescriptions 
improving tumor control and reducing toxicity [7, 27].
Predicting renal damage
In recent years, the study of acute kidney injury has been 
facilitated by the increasing availability of stored demo-
graphic and clinical patient data [28, 29]. The Chronic 
Database of Kidney Diseases (CDKD), for example, is a 
database system designed to hold personal and laboratory 
investigatory details of patients with renal disease (http://
www.cdkd.org/). Its goal is to make kidney-related physi-
ological data easily available to the scientific community. 
CDKD currently contains more than 10,000 public data 
entries, available upon free registration  [30]. Unfortu-
nately, most datasets do not provide standardized informa-
tion, and do not allow differentiation between acute and 
chronic disease. This heterogeneity may hinder compari-
sons and underestimate disease burden, limiting its applica-
tion in a clinical setting [28].
Collecting information on kidney functional status could 
be particularly useful in cancer patients. These patients 
frequently repeat CT examinations for staging or assess-
ment of response to treatment, in which administration of 
intravenous iodine contrast agent is generally required. It 
is well known that iodinated contrast agents are associated 
with an increased risk of contrast-induced nephrotoxicity; 
the risk is particularly high in patients that have impaired 
renal function and diabetes [31]. Furthermore, renal fail-
ure in oncological patients is often multifactorial and more 
common than in the general population [32]. The risk of 
complications from contrast medium administration is 
compounded by advanced age, dehydration, the number 
of times CT is repeated, and co-administration of nephro-
toxic chemotherapeutic drugs. Thus, identification of fac-
tors predicting contrast-induced nephrotoxicity is important 
to avoid potentially serious complications, related to acute 
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Oncological patient management is more and more a 
complex matter requiring constant monitoring throughout 
chemotherapy lines, radiation therapy sessions, scheduled 
follow-up assessments, etc. Thus, information collected 
from the very first diagnosis to outcome of every single 
patient is growing fast. To date, most of this information is 
passively accumulated by hospitals within PACS and RIS 
facilities. Conversely, in an integrated healthcare system, 
where interdisciplinary teams of specialists act together, 
all information should be linked with the aim of optimizing 
individual patient care, paving the way to truly personal-
ized medicine.
To optimize current oncological workflows, it will be 
necessary to develop event-tracking systems in which 
monitoring points based on checklists are implemented. 
A good system should be able to identify workflow issues 
and technical errors in every step of patient management, 
advancing department quality control and improving exist-
ing processes or implementing new workflows [33]. Each 
patient in the processing chain will thus contribute to help 
clinicians and technicians to detect workflow inefficiencies, 
as incorrectly transmitted images or information during 
disease assessment, or delays in scheduled follow-ups. A 
patient tracking system would also simplify pinpointing the 
sources of error or mismatching within processes, produc-
ing as a result an honest picture of the current events, and 
enhance the ability to respond in real time. The opportu-
nity at hand using big data is the ability to scan and connect 
massive repositories with the aim of providing new insights 
on patient workflow. Correlating clinical data with costs, 
outcomes, and performances will also support the develop-
ment of evidence-based guidelines and clinical best prac-
tices. In the end, again, all of this will improve patient’s 
access to treatment, reduce therapy side effects, and con-
tribute to improve his quality of life and, on a population 
scale, allow healthcare systems to save more lives and con-
tain costs.
Conclusions
The possibility to extract new knowledge from the huge 
amount of increasingly available unstructured data is 
crucial for advances in cancer diagnosis and treatment. 
Indeed, the strength of big data lies in its volume and 
variety. However, this process is not without challenges 
as big data analysis also has several intrinsic limitations, 
which limit its use. First, big data is usually extremely het-
erogeneous, can be missing, non-interpretable, conflict-
ing, inaccurate, or stored in different locations. Second, it 
may be beyond human capabilities to analyze. Indeed, the 
very point of looking to big data is “to identify patterns 
that create answers to questions you didn’t even know to 
ask” [34]. Finally, big data analysis may breach patient 
privacy. Therefore, the success of big data in creating 
healthcare value may require some changes in the current 
polices, to balance the potential societal benefits of big data 
approaches and the protection of patients’ confidentiality 
[35].
In conclusion, the benefits of large-scale data mining to 
the oncologic patient are slowly emerging. Big data initia-
tives could be instrumental in improving the management 
and the quality of life of each individual cancer patient 
based on the results of imaging biomarker analysis or on 
the implementation of event-tracking systems. On a macro-
economics level, big data could support the implementation 
of evidence-based guidelines and of quality control meas-
ures, in the end reducing system inefficiencies. Because of 
their intrinsic heterogeneity, it will be very challenging to 
fully exploit big data.
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